TACTILE SYSTEMS TECHNOLOGY INC (TCMD)
Health Care · Home healthcare medical devices; pneumatic compression and airway clearance therapy · NASDAQ
A medical device company delivering at-home pneumatic compression and airway clearance solutions for lymphedema, vascular disease, and chronic respiratory conditions.
What TACTILE SYSTEMS TECHNOLOGY INC does
Tactile Medical develops and commercializes medical devices for treating underserved chronic diseases in the home setting. The company operates a direct-to-patient and -provider model for its lymphedema portfolio (Flexitouch Plus, Entre Plus, and Nimbl pneumatic compression systems) and uses a DME distribution model for its AffloVest airway clearance device. Lymphedema products represent 83–84% of revenue, while airway clearance represents approximately 17%. The company focuses on advancing the standard of care for lymphedema, chronic venous insufficiency, oncology-related lymphedema, and chronic respiratory conditions.
Themes: ["Lymphedema treatment"]
Fundamentals
- Price$30.68 as of 2026-07-09 close
- Market cap$691M as of 2026-07-10
- 1-year return+202.9% as of 2026-07-09 close
- P/E34.04 as of 2026-07-10
- Net margin+5.9% as of 2026-07-10
- Gross margin+51.3% as of 2026-07-10
- ROE+9.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+17.2% as of 2026-07-10
- Revenue CAGR (3y)+10.1% SEC XBRL
- Beta0.81 as of 2026-07-10
Key risks (from latest filing)
["Regulatory dependence: All products require FDA clearance; delays or denials in premarket reviews could impact commercial launches and product portfolio expansion."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.